Israel's Cancer Care Funding Lags Behind Medical Advances
Translated & summarized from Vesty by baba
Israel's state-funded health basket for cancer treatment faces a significant shortfall, with an annual budget of 650 million shekels unable to cover the estimated 3 billion shekels in applications for new drugs and technologies. This static funding struggles to keep pace with rapidly advancing medical costs and treatments, despite Israel having a modern oncology system. The author contrasts this with the dire situation in other countries, urging gratitude for accessible care.
The story in 5 lines · by baba
- Israel's annual budget for new cancer drugs and technologies is 650 million shekels.
- Medical professionals submit applications for new cancer treatments valued at approximately 3 billion shekels annually.
- The static state funding for Israel's health basket lags behind rising medical costs and technological advancements.
- Cancer treatment costs vary significantly between the U.S., Western Europe, and Eastern Europe.
- The author highlights the case of a Moldovan patient reliant on public donations for medication.
While the United States leads in cancer care spending, with costs exceeding $200 billion annually, European nations allocate 4-8% of their healthcare budgets to oncology. Significant disparities exist within Europe, with countries like Germany and Switzerland spending 2.5 times more per capita than Eastern European nations. Drug costs also vary widely, with monthly cancer treatment in the U.S. costing approximately $11,755, compared to about $8,000 in Germany and $6,950 in Switzerland.
In Israel, cancer treatment is funded through the state's health basket, known as "sal habriut." This basket covers medications, diagnostics, surgeries, and preventive programs. However, inclusion in the basket does not guarantee access, as patients must meet specific medical criteria. Annually, the government allocates an additional 650 million shekels for new drugs and technologies. This budget, which has remained static for years, is insufficient to cover the estimated 3 billion shekels worth of applications submitted by medical professionals for new treatments each year.
The static funding means that Israel's advanced oncology system struggles to keep pace with rapidly advancing medical technologies and drug development. While the state aims to provide comprehensive care, the growth in state funding for the health basket has not matched the increasing costs of innovative treatments, including targeted and immunotherapy, diagnostics, and radiation therapy equipment.
The author contrasts Israel's situation with that of patients in countries where treatment is often inaccessible, citing the case of Iulia Zaremba in Moldova, who relies on public donations for a life-saving medication. This comparison serves to highlight that despite funding challenges, Israelis have access to a system that, while needing improvement, is still significantly more accessible than in many other parts of the world, urging a sense of gratitude among patients.